ALARA and Radiation Safety
|
|
- Jesse Morgan
- 6 years ago
- Views:
Transcription
1 ALARA and Radiation Safety Experience the power of TheraSphere and deliver hope where it s needed most. Imagine where we can go. btg-im.com
2 What is TheraSphere? TheraSphere is indicated for radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters. The device is also indicated for HCC patients with partial or branch portal vein thrombosis/ occlusion, when clinical evaluation warrants the treatment. 3 TheraSphere : Consists of insoluble glass microspheres where yttrium-90 ( 90 Y) is an integral constituent of the glass 3 Has a mean microsphere diameter of 20 to 30 μm 3 Is a pure beta emitter with an average energy of MeV and physical half-life of 64.1 hours (2.67 days) 3 Is calibrated to U.S. National Institute of Standards and Technology (NIST) standards 9 The recommended dose for TheraSphere administered to the liver is between Gy ( ,000 rad). 3, * TheraSphere dose vial Radiation exposure to the healthcare professional during TheraSphere treatment is well below the amount of exposure from a US coast-to-coast flight. 10,11 * Please refer the TheraSphere Package Insert for complete dosing calculations and administration instructions.
3 What is ALARA? Power Where You Need It As Low As Reasonably Achievable The use of radiation for beneficial purposes in medical procedures is a major contributor to improved human health. However, the benefits of treatment need to be balanced with the risks of radiation exposure. ALARA is a radiation safety principle of keeping unneccessary radiation exposure and release of radioactive materials to the environment as low as can be achieved by employing all reasonable methods. 1 ALARA is also a regulatory requirement for all radiation safety programs. ALARA is based on the assumption that exposure to radiation of any dose increases the probability of detrimental biological effects such as genetic mutations and cancer. ALARA can be achieved using three key factors: 1. TIME Reducing exposure time reduces radiation risk. 2. DISTANCE Doubling the distance reduces radiation exposure four-fold. 3. SHIELDING Shielding material absorbs radiation between the source and the individual. Adapted from Brateman L, ALARA = As Low As Reasonably Achievable
4 How Does the TheraSphere Dose Vial Conform to ALARA? TheraSphere was designed with ALARA in mind to reduce radiation exposure to both healthcare professionals and patients to As Low As Reasonably Achievable levels. Dose vials are ready to use 3 Both the shipping vial and the administration vial are ONE AND THE SAME NO dose preparation or manipulation is required Rapid infusion means that delivery is quick, with an infusion time of less than 5 minutes 4 NO continuous fluoroscopy or contrast is needed during administration 4 Preparation (priming) of the administration system tubing is performed independent of the dose vial 3 Protection is provided by acrylic and lead shielding around the dose vial during shipping AND patient treatment 3 Acrylic shield blocks 100% of the beta radiation 3 Lead pot reduces Bremsstrahlung radiation exposure to 1/7 th of levels without lead shielding 3,5 NO significant amount of free 90 Y present in the treatment vial 5 Minimizing radiation exposure to patients and others: NO significant amount of 90 Y leaches from the glass matrix 5 Secondary radiation exposure to others is well below regulatory limits 5 Body fluid radioactivity is NOT an issue for TheraSphere patients 5 There is NO need for special precautions regarding body fluids (urine, stool, blood, or vomit) Patient hygiene instructions are NOT necessary High delivery efficiency means less 90 Y in waste materials that need to be handled after patient treatment 4 90 Y = yttrium-90; ALARA = As Low As Reasonably Achievable
5 How Does the Administration Accessory Kit Conform to ALARA? The TheraSphere Administration Accessory Kit is designed and constructed to SHIELD healthcare professionals and patients from radiation exposure to As Low As Reasonably Achievable levels. TheraSphere Administration Accessory Kit: Provides 100% beta shielding to the user through the acrylic shield 3,6 Is supplied with a 2 L waste jar with beta shield for handling and storing post-treatment waste 3 Is designed to contain any potential leaks from the dose vial (although leaks are exceedingly rare) 7 Lead pot containing dose vial 2 L waste jar with beta shield Dosimeter Acrylic shield Administration Accessory Kit ALARA = As Low As Reasonably Achievable Adapted from the TheraSphere website: 8
6 Additional Product Information Indication for Use Authorized by Federal Law under a humanitarian device exemption (HDE) for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable HCC who can have placement of appropriately positioned hepatic arterial catheters. The device is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment. The effectiveness of this device for this use has not been demonstrated. 3 Important Safety Information Caution Federal (USA) law restricts this device to sale by or on the order of a physician with appropriate training and experience. 3 Warnings A retrospective study of 121 patients from five clinical trials has shown that the following five Pre-treatment High Risk Factors have been associated with at least 48% of all serious adverse events that were possibly related to use of the device and with 11 of the 12 deaths that were possibly related to use of the device: Infiltrative tumor type Bulk disease (tumor volume >70% of the target liver volume, or tumor nodules too numerous to count) The physician should always take the above-noted Pre-treatment High Risk Factors into consideration for each patient when making decisions regarding the use of TheraSphere for treatment. 3 Contraindications The use of TheraSphere is contraindicated in patients: 3 whose Tc-99m MAA hepatic arterial perfusion scintigraphy shows any deposition to the gastrointestinal tract that may not be corrected by angiographic techniques who show shunting of blood to the lungs that could result in delivery of greater than 16.5 mci of yttrium-90 to the lungs. Radiation pneumonitis has been seen AST or ALT >5 ULN Bilirubin >2 mg/dl Tumor volume >50% combined with an albumin <3 g/dl in patients receiving doses to the lungs greater than 30 Gy in a single treatment in whom hepatic artery catheterization is contraindicated; such as patients with vascular abnormalities or bleeding diathesis who have severe liver dysfunction or pulmonary insufficiency who are pregnant Adverse Events The most common adverse events ( 5%) include elevated bilirubin (23.1%), ascites (8.3%), abdominal pain (6.6%), and elevated AST/ALT (5.8%). 3 Please see the full TheraSphere Package Insert available at for complete important safety information, including BOXED WARNINGS. References: 1. Canadian Nuclear Safety Commission. Regulatory Guide: Keeping Radiation Exposures and Doses As Low as Reasonably Achievable (ALARA). G-129, Revision 1, October Brateman L. Radiographics 1999;19(4): Package Insert TheraSphere Yttrium-90 Glass Microspheres Rev. 12. Biocompatibles UK Ltd, a BTG International group company. Available at: physicians-package-insert/ts_packageinsert_usa_v12.pdf. 4. Salem R, Thurston KG. J Vasc Interv Radiol 2006;17: U.S.A. TheraSphere Reference Manual (PCCS 550A). 6. McGhee S, Data on file, July 11, McGhee S, Data on file, July 3, BTG International Canada Inc. com. Accessed July 14, Cessna JT, communication, April 8, United States Nuclear Regulatory Commission (U.S. NRC). Measuring Radiation. Updated June 28, 2013; accessed July 22, McGhee S, Data on file, July 18, Hilgard P, Hamami M, Fouly AE, et al. Hepatology 2010;52(5): Mazzaferro V, Sposito C, Bhoori S, et al. Hepatology 2013;57(5): ALT = alanine aminotransferase; AST = aspartate aminotransferase; Tc-99m MAA = technetium-99m macroaggregated albumin; ULN = upper limit of normal Power Where You Need It Imagine where we can go. Humanitarian Device. TheraSphere is authorized by Federal Law for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma (HCC) who can have placement of appropriately positioned hepatic arterial catheters. The device is also indicated for HCC patients with partial or branch portal vein thrombosis/occlusion, when clinical evaluation warrants the treatment. The effectiveness of this device for this use has not been demonstrated. 3 Common adverse effects include fatigue, pain, and nausea. The majority of adverse effects are mild to moderate in severity and are manageable or resolve over time. For details on rare or more severe adverse effects, please refer to the TheraSphere Package Insert at 3,12,13 TheraSphere is manufactured for Biocompatibles UK Ltd, a BTG International group company. TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. Power Where You Need It and Power You Can Trust are trademarks of Biocompatibles UK Ltd. Imagine where we can go is a trademark of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. All rights reserved BTG International Canada Inc. US-USTHSP btg-im.com
Minimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go.
ALARA & RADIATION SAFETY Minimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go. What is ALARA? As Low As Reasonably Achievable The use of radiation
More informationMinimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go.
ALARA & RADIATION SAFETY Minimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go. What is ALARA? As Low As Reasonably Achievable The use of radiation
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationA Patient s Guide to TheraSphere. Important Information for People with Liver Cancer
A Patient s Guide to TheraSphere Important Information for People with Liver Cancer A Patient s Guide to TheraSphere Contents Your physician has prescribed TheraSphere as a treatment, this booklet contains
More informationSELECTIVE INTERNAL RADIATION THERAPY FOR TREATMENT OF LIVER CANCER
SELECTIVE INTERNAL RADIATION THERAPY FOR TREATMENT OF LIVER CANCER SIR-Spheres*: A New Treatment Option for Non-Resectable Liver Tumors Treatment Overview SIRT: Selective Internal Radiation Therapy Concept
More informationFuture Needs for Standards in 90 Y Microsphere Therapy. CIRMS 2012 Reed Selwyn, PhD, DABR 24 October 2012
Future Needs for Standards in 90 Y Microsphere Therapy CIRMS 2012 Reed Selwyn, PhD, DABR 24 October 2012 Objectives I. General Description Microsphere Distribution Product Comparison II. Dosimetry Models
More informationTheraSphere Yttrium-90 Glass Microspheres Instructions for Use
TheraSphere Yttrium-90 Glass Microspheres Instructions for Use English 990252.SPE Rev. 8 DESCRIPTION TheraSphere Yttrium-90 Glass Microspheres Instructions for Use Sterile, single use, Yttrium-90 glass
More informationY-90 Microsphere Therapy: Nuclear Medicine Perspective
Y-90 Microsphere Therapy: Nuclear Medicine Perspective Carl Hoh, M.D. Dept. Radiology UCSD Medical Center ckhoh@ucsd.edu Learning Objectives Role of Nuclear Medicine in patient selection Technical Issues
More informationDisclosures. I am on the Onyx speaker bureau I am a paid consultant to. Boston Scientific CeloNova Cook MDS Nordion Sirtex
Disclosures I am on the Onyx speaker bureau I am a paid consultant to Boston Scientific CeloNova Cook MDS Nordion Sirtex Comparing Y90 Devices Matthew S. Johnson MD, FSIR Indiana University School of Medicine
More informationSIRT Dosimetry: Sometimes Less Is More
SIRT Dosimetry: Sometimes Less Is More Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director, Radiation Oncology,
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More informationSelective Internal Radiation Therapy. Jefferson R. Pagsisihan, MD, DPSNM The Medical City St. Luke s Medical Center
Selective Internal Radiation Therapy Jefferson R. Pagsisihan, MD, DPSNM The Medical City St. Luke s Medical Center S Selective Internal Radiation Therapy catheter-based liver directed modality for patients
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationMartin Law, PhD, DABSNM, DABMP Physicist ic Radiology/QMH
A practical measure in personnel dose reduction for 90 Y-micropsheres liverdirected radioembolization: from radiology department to patient ward Martin Law, PhD, DABSNM, DABMP Physicist ic Radiology/QMH
More informationRadioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases
Radioembolization with Lipiodol for the Treatment of Hepatocellular Carcinoma and Liver Metastases Pr Francesco Giammarile CHLS Lyon Faculté de Lyon Sud «Aut tace aut loquere meliora silentio» Malignant
More informationSIRT in Neuroendocrine Tumors
SIRT in Neuroendocrine Tumors Marnix G.E.H. Lam, MD PhD Professor of Nuclear Medicine AVL Amsterdam UMC Utrecht ENETS Center of Excellence, The Netherlands Disclosure of speaker s interests Consultant
More informationIntra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization
Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization Department of Radiology, National Cancer Center In Joon Lee Contents Conventional TACE Role of TACE in management
More informationTransarterial Chemoembolisation (TACE) with Drug-Eluting Beads
Transarterial Chemoembolisation (TACE) with Drug-Eluting Beads A minimally invasive treatment for liver cancer Provided as an educational service by Biocompatibles UK Ltd, a BTG International group company
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationCanadian Package Insert TheraSphere Yttrium-90 Glass Microspheres
Description Canadian Package Insert TheraSphere Yttrium-90 Glass Microspheres TheraSphere consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass [1]. The mean
More informationHepatocellular Carcinoma (HCC)
Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College
More informationYTTRIUM-90 MICROSPHERES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A REVIEW
doi:10.1016/j.ijrobp.2006.02.061 Int. J. Radiation Oncology Biol. Phys., Vol. 66, No. 2, Supplement, pp. S83 S88, 2006 Copyright 2006 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/06/$
More informationStaging & Current treatment of HCC
Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt
More informationA Guide for Patients Living with a Biliary Metal Stent
A Guide for Patients Living with a Biliary Metal Stent What is a biliary metal stent? A biliary metal stent (also known as a bile duct stent ) is a flexible metallic tube specially designed to hold your
More informationRuby Coil. Large Volume Detachable Coils
Ruby Coil Ruby Case Examples 38 mm Hepatic Artery Aneurysm Pulmonary AVM 2 Coils Dr. James Benenati Miami Cardiac and Vascular Institute, FL Y90 Embolization Type 2 Endoleak Dr. J Moskovitz Florida Hospital,
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of selective internal radiation therapy for primary liver cancer Selective internal
More informationRadioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis
Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis Mercedes Iñarrairaegui, MD, PhD, Kenneth G. Thurston, MA, Jose I. Bilbao,
More informationY-Microspheres Radioembolization for Selective Internal Radiation Therapy of Primary and Metastatic Cancer in the Liver
90 Y-Microspheres Radioembolization for Selective Internal Radiation Therapy of Primary and Metastatic Cancer in the Liver Pr Francesco Giammarile CHLS Lyon Faculté de Lyon Sud «Aut tace aut loquere meliora
More informationRadioembolization for the treatment of hepatocellular carcinoma
pissn 2287-2728 eissn 2287-285X Review https://doi.org/10.3350/cmh.2017.0004 Clinical and Molecular Hepatology 2017;23:109-114 Radioembolization for the treatment of hepatocellular carcinoma Hyo-Cheol
More information1/13/2014 Ries et al (eds). At: 2
1/13/2014 1 1/13/2014 Ries et al (eds). At: http://seer.cancer.gov/csr/1975_2002 2 1/13/2014 Coldwell et al, General Selection Criteria of Patients for Radioembolization of Liver Tumors AJCO 2010 3 1/13/2014
More informationSORAMIC: NM Procedures
: NM Procedures J. Ruf Klinik für Radiologie und Nuklearmedizin : NM Procedures Evaluation - 99m Tc MAA Scintigraphy Lung shunt assessment Treatment activity determination Therapy - 90 Y-SIR-Spheres Procedure
More informationRadioembolization of the Liver. Michael Meuse, M.D. Vascular and Interventional Radiology
Radioembolization of the Liver Michael Meuse, M.D. Vascular and Interventional Radiology Brachytherapy Principle Radiation is accepted as a standard treatment option for liver cancer Radiation will break
More informationSystem.
System www.penumbrainc.com POD System Case Examples 45 cm of POD Packing Coil in 1.5 to 3 mm diameter dilating vessel Bronchial Artery Embolization Dr. Amit Kakkar and Dr. Aksim Rivera, Bronx, NY Inflow:
More informationTrans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?
Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:
More informationINCIDENTAL FINDING DURING CARDIOMYOPATHY WORKUP
Originally Posted: February 01, 2015 INCIDENTAL FINDING DURING CARDIOMYOPATHY WORKUP Resident(s): Mariya Gusman, M.D. Attending(s): Raul Palacios, M.D. Program/Dept(s): Brooke Army Medical Center DISCLAIMER
More informationHelping you access curative therapies for liver cancer patients
Metastatic colorectal cancer (mcrc) Helping you access curative therapies for liver cancer patients Biocompatibles Excellence in Interventional Oncology Biocompatibles UK Ltd is a BTG International group
More informationTRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD
UNIVERSITY OF PRETORIA STEVE BIKO ACADEMIC HOSPITAL SOUTH AFRICA TRANSEARTERIAL CHEMO- EMBOLIZATION FOR HEPATIC METASTASES FROM NEURO-ENDOCINE NEOPLASIA AND HEPATOMA DR SAMIA AHMAD 1 INTRODUCTION Hepatic
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationRadioembolization (Y90)
Scan for mobile link. Radioembolization (Y90) Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationRoutine monitoring requirements for your mcrpc patients on Xofigo
XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign
More informationDOSIMETRY PRODUCTS & SERVICES 2018 PRICE LIST
DOSIMETRY PRODUCTS & SERVICES 2018 PRICE LIST Dosimetry Products & Services Dosimetry and Calibration Products and Services All prices are in Canadian Dollars. Delivery for most items is 6 weeks subject
More informationSIR-Spheres microspheres
SIR-Spheres microspheres Training Program Physicians and Institutions SIRTEX MEDICAL LIMITED Level 33, 101 Miller Street North Sydney NSW 2060 Australia Tel: +61 29964 8400 Fax: +61 2 9964 8410 SIRTEX
More informationHepatocellular carcinoma (HCC) is a global
Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term Survival Philip Hilgard, 1 Monia Hamami, 2 Amr El Fouly, 1 André Scherag, 3
More informationGuide for Use. Advance Plus Touch Free Intermittent Catheter System
Advance Plus Touch Free Intermittent Catheter System Guide for Use Hollister Advance Plus intermittent catheter features Touch Free technique enabling users to catheterize with confidence virtually anytime,
More informationRadioembolization: technical aspects
Radioembolization: technical aspects Rita Golfieri Unità Operativa Radiologia Malpighi Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola - Malpighi La sottoscritta dichiara di non aver
More informationRoutine monitoring requirements for your mcrpc patients on Xofigo
XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign
More informationSodium Iodide I 131 Solution. Click Here to Continue. Click Here to Return to Table of Contents
Sodium Iodide I 131 Solution Package inserts are current as of January, 1997. Contact Professional Services, 1-888-744-1414, regarding possible revisions Click Here to Continue Click Here to Return to
More informationY90 SIRT Therapy Dosimetric Aspects
Y90 SIRT Therapy Dosimetric Aspects David Chee-Eng Ng MBBS, BSc, MSc, MRCP, FAMS, FRCP (Edin) Head and Senior Consultant, Department of Nuclear Medicine and PET Singapore General Hospital Adjunct Assistant
More informationClinical trials evaluating the use of Yttrium-90. Copyright HMP Communications
Optimizing Reimbursement for Radioembolization: The Importance of Adequate Documentation Rishi Chopra, MS 1 ; Jason C. Hoffmann, MD 1 ; Amanjit S. Baadh, MD 2 From 1 Winthrop University Hospital, Department
More informationCATHETER ACCESS KIT. For use with Prometra Programmable Infusion Systems
CATHETER ACCESS KIT Caution: Federal (USA) Law restricts this device to sale by or on the order of a physician. Table of Contents Contents... 3 Description... 3 Indications... 3 Contraindications... 3
More informationROTABLATORTM. Peripheral. Rotational Atherectomy System. Quick Reference Cards
Peripheral ROTABLATORTM Rotational Atherectomy System Quick Reference Cards Technical Assistance: 1.800.949.6708 Customer Service: 1.888.272.1001 Complaints: 1.800.811.3211 Setup Video: www.bostonscientific.com/rotablatorsetup
More informationDC Bead Chemoembolisation for the Treatment of Primary [DEBDOX ] and Secondary [DEBIRI ] Liver Cancer Review of Published Clinical Data
DC Bead Chemoembolisation for the Treatment of Primary [DEBDOX ] and Secondary [DEBIRI ] Liver Cancer Review of Published Clinical Data Professor Thomas J Vogl Goethe University Hospital Frankfurt-am-Main,
More informationCP STENT. Large Diameter, Balloon Expandable Stent
CP STENT Large, Expandable CP STENT OPTIONS 12mm to Expansion 26mm to Expansion CP Matrix (number of zigs) 1.6 2.2 2.8 3.4 3.9 4.5 5 5.5 6 12 14 15 16 18 20 22 24 26 28 30 CP Details: CP is composed of
More informationCorrespondence should be addressed to O. Audrain;
International Hepatology Volume 2013, Article ID 827649, 8 pages http://dx.doi.org/10.1155/2013/827649 Clinical Study Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated
More informationInstructions for Use Reprocessed LASSO Circular Mapping Diagnostic Electrophysiology (EP) Catheter
Instructions for Use Reprocessed LASSO Circular Mapping Diagnostic Electrophysiology (EP) Catheter Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. DEVICE DESCRIPTION
More informationHepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization
Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization JP King PGY2 May 22, 2015 Neuroendocrine Tumor (NET) WHO Classification Location
More informationACR SIR PRACTICE PARAMETER FOR RADIOEMBOLIZATION WITH MICROSPHERE BRACHYTHERAPY DEVICE (RMBD) FOR TREATMENT OF LIVER MALIGNANCIES
The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College
More informationBosentan Accord Prescriber s Guide. This guide provides important safety information about Bosentan Accord regarding the risk
Bosentan Accord Prescriber s Guide This guide provides important safety information about Bosentan Accord regarding the risk of liver injury and birth defects. Information is provided concerning the monitoring
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationhqtace The Next Generation in Liver Cancer Treatment
HepaSphere Microspheres Quality Targeted to the tumor Absorbs drug Conforms to the vessel Elutes and embolizes hqtace The Next Generation in Liver Cancer Treatment Quality TACE hqtace The No-Compromise
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: September 15, 2017 Kynamro Description Kynamro
More informationPromacta. Promacta (eltrombopag) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.15 Subject: Promacta Page: 1 of 6 Last Review Date: September 15, 2017 Promacta Description Promacta
More informationHepatocellular carcinoma (HCC) is a highly prevalent
Dosimetry Based on 99m Tc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with 90 Y-Loaded Glass Microspheres: Preliminary
More informationBrachytherapy, Noncoronary
Brachytherapy, Noncoronary Policy Number: Original Effective Date: MM.05.004 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 03/01/2016 Section: Radiology Place(s) of
More informationPART I. RADIONUCLIDE THERAPY WITH I-131 SODIUM IODIDE: PATIENT & DOSE ADMINISTRATOR PRECAUTIONS; ADMINISTRATION METHODS
OVERVIEW AND TOPICS Patient and dose administrator precautions and dose administration methods of therapeutic procedures Administration methods for performing therapy with I-131 sodium iodide in either
More informationGLUCEPTATE. Technetium Tc 99m Gluceptate Kit DIAGNOSTIC DESCRIPTION
27194 0001E m TM GLUCEPTATE Technetium Tc 99m Gluceptate Kit DIAGNOSTIC DESCRIPTION The kit consists of reaction vials which contain the sterile, non-pyrogenic, nonradioactive ingredients necessary to
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple
More informationPERFORMANCE YOU CAN TRUST. EverFlex Self-expanding Peripheral Stent with Entrust Delivery System
PERFORMANCE YOU CAN TRUST EverFlex Self-expanding Peripheral Stent with Entrust Delivery System The Entrust Delivery System is designed to provide improved patient outcomes and procedural efficiency. The
More informationJanuary Coding Guide. Pre-Treatment Mapping and Microspheres Administration. Hospital Outpatient, ASC and Physician Services
January 2018 Coding Guide Pre-Treatment Mapping and Microspheres Administration Hospital Outpatient, ASC and Services What are SIR-Spheres Y-90 resin microspheres? SIR-Spheres Y-90 resin microspheres are
More informationIn- and exclusion criteria
In- and exclusion criteria Kerstin Schütte Department of Gastroenterology, Hepatology and Infectious Diseases University of Magdeburg Overview: Study population Inclusion criteria I - General criteria
More informationGuide for Use. Apogee Plus Touch Free Intermittent Catheter System
Apogee Plus Touch Free Intermittent Catheter System Guide for Use Touch free, sterile, and self-contained, Hollister Apogee Plus intermittent catheter empowers you to maintain your independence and live
More informationUnderstanding Your Fluid Status During Dialysis and the Crit-Line. IV Monitor
Understanding Your Fluid Status During Dialysis and the Crit-Line IV Monitor IV 1 Understanding Your Fluid Status During Hemodialysis Welcome to understanding your fluid status during hemodialysis. This
More informationRADIATION SAFETY REFRESHER TRAINING FOR AUGUSTA UNIVERSITY USERS OF RADIOACTIVE MATERIAL
RADIATION SAFETY REFRESHER TRAINING FOR AUGUSTA UNIVERSITY USERS OF RADIOACTIVE MATERIAL Environmental Health and Safety Division Course Content Radiation Safety Radiation Dose Limits and Dosimetry Postings
More informationALECENSA (alectinib) oral capsule
ALECENSA (alectinib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationMYLOTARG (gemtuzumab ozogamicin)
MYLOTARG (gemtuzumab ozogamicin) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationGALLIUM CITRATE Ga 67 INJECTION
511945-0903 September 2003 USA Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, MA 01862 USA GALLIUM CITRATE Ga 67 INJECTION FOR DIAGNOSTIC USE DESCRIPTION: Gallium Citrate Ga 67
More informationRadiation Safety General Awareness and ALARA Training
Radiation Safety General Awareness and ALARA Training Authorized User The following materials should be used to provide training to laboratory personnel that do not use radioactive material. Have each
More informationPeel-Apart Percutaneous Introducer Kits for
Bard Access Systems Peel-Apart Percutaneous Introducer Kits for Table of Contents Contents Page Bard Implanted Ports Hickman*, Leonard*, Broviac*, Tenckhoff*, and Groshong* Catheters Introduction....................................
More informationBTK Case Studies Joseph Cardenas, MD AZ Heart & Vascular, Yuma, AZ
BTK Case Studies Joseph Cardenas, MD AZ Heart & Vascular, Yuma, AZ 1 Case 1 78 yr. old female Rutherford Class II/III lesion 1 block claudicant 2 Pre Treatment Post Treatment Anterior Tibial Artery Occlusion
More informationTransjugular liver access and biopsy
Transjugular liver access and biopsy An illustrated guide Illustrations by Lisa Clark LABS LIVER ACCESS AND BIOPSY SET MEDICAL Support your procedures by using products that are specifically designed for
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationR: March, E D T P A. Kit for the Preparation of Technetium Tc 99m Pentetate Injection. DIAGNOSTIC - For Intravenous Use
R: March, 1998 27227 0002E m TM DESCRIPTION D T P A Kit for the Preparation of Technetium Tc 99m Pentetate Injection DIAGNOSTIC - For Intravenous Use Each kit consists of reaction vials which contain the
More information8/1/2017. Disclosures. Outline. SAM Imaging Education Course 90Y-Microsphere Therapy: Emerging Trends and Future Directions
SAM Imaging Education Course Y-Microsphere Therapy: Emerging Trends and Future Directions Matt Vanderhoek, PhD Henry Ford Health System, Detroit, MI Vanessa Gates, MS Northwestern University, Chicago,
More informationArm A: Induction Gemcitabine 1000 mg/m 2 IV once a week for 6 weeks.
ECOG-4201 (RTOG Endorsed) ECOG 4201 Pancreas (RTOG Endorsed)-1 Protocol Status: Opened: April 10, 2003 Closed: December 15, 2005 Title: A Randomized Phase III Study of Gemcitabine in Combination with Radiation
More informationTechnical Considerations in Zevalin Radioimmunotherapy Kathy Thomas, MHA, CNMT City of Hope National Medical Center
Technical Considerations in Zevalin Radioimmunotherapy Kathy Thomas, MHA, CNMT City of Hope National Medical Center Technical Considerations in Zevalin Radioimmunotherapy Objectives: Explain the technical
More informationJanuary Coding Guide. Pretreatment Mapping and Microspheres Administration. Hospital Outpatient, ASC OBIS and Physician Services
January 2019 Coding Guide Pretreatment Mapping and Microspheres Administration Hospital Outpatient, ASC OBIS and Services What are SIR-Spheres yttrium-90 resin microspheres? SIR-Spheres Y-90 resin microspheres
More informationCOMPARING Y90 DEVICES
COMPARING Y90 DEVICES William S Rilling MD, FSIR Professor of Radiology and Surgery Director, Vascular and Interventional Radiology Medical College of Wisconsin DISCLOSURES Research support : Siemens,
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationSafeTview Syringe Shields Models to Latchkey Syringe Shields Models to Nuclear Medicine. Specifications.
SafeTview Syringe Shields Models 56-342 to 56-345! Best shielding syringe shield with a window. Window is reset into offset solid tungsten barrel to prevent shine-through as occurs with other designs!
More informationRadiation Safety Guide. Analytical X-Ray Equipment
Radiation Safety Guide Analytical X-Ray Equipment Table of Content Page 1. Radiation 2 A. Radiation Quantities 2 B. Background Radiation 2 C. Biological Effect of Radiation 3 D. Radiation Injury To The
More informationClick Here to Continue. Click Here to Return to Table of Contents
TechneScan Gluceptate Package inserts are current as of January, 1997. Contact Professional Services, 1-888-744-1414, regarding possible revisions. Click Here to Continue Click Here to Return to Table
More informationPRIOR AUTHORIZATION Prior authorization is required for BlueCHiP for Medicare members and recommended for Commercial products.
Medical Coverage Policy Radioembolization for Primary and Metastatic Tumors of the Liver EFFECTIVE DATE: 10 06 2009 POLICY LAST UPDATED: 08 02 2016 OVERVIEW Radioembolization (RE), referred to as selective
More informationGuide for Use. Apogee Plus Touch Free Intermittent Catheter System
Apogee Plus Touch Free Intermittent Catheter System Guide for Use Touch free, sterile, and self-contained, Hollister Apogee Plus intermittent catheter empowers you to maintain your independence and live
More informationBrachytherapy, Noncoronary
Brachytherapy, Noncoronary Policy Number: Original Effective Date: MM.05.004 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2017 Section: Radiology Place(s) of
More informationPost-Y90 Radioembolisation imaging with bremsstrahlung SPECT-CT and PET-CT
Post-Y90 Radioembolisation imaging with bremsstrahlung SPECT-CT and PET-CT Poster No.: C-2264 Congress: ECR 2012 Type: Scientific Exhibit Authors: S.-C. M. Wang, S. Evans, B. Camden, D. Farlow; Westmead,
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: December 2, 2016 Kynamro Description Kynamro (mipomersen)
More informationDevice Preparation (all steps to be performed per standard interventional technique)
sertera Biopsy Device Instructions for Use Please read all information carefully. Failure to properly follow the instructions may lead to unintended consequences. Important: This package insert is designed
More information